Abstract:Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons and excessive microglial activation in the substantia nigra pars compacta (SNpc). In the present study, we aimed to demonstrate the therapeutic effectiveness of the potent sphingosine-1-phosphate receptor antagonist fingolimod (FTY720) in an animal model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and to identify the potential mechanisms underlying these therapeutic effects. C57BL/6J mice were orally administered FTY720 before subcutaneous injection of MPTP. Open-field and rotarod tests were performed to determine the therapeutic effect of FTY720. The damage to dopaminergic neurons and the production of monoamine neurotransmitters were assessed using immunohistochemistry, high-performance liquid chromatography, and flow cytometry. Immunofluorescence (CD68- positive) and enzyme-linked immunosorbent assay were used to analyze the activation of microglia, and the levels of activated signaling molecules were measured using Western blotting. Our findings indicated that FTY720 significantly attenuated MPTP-induced behavioral deficits, reduced the loss of dopaminergic neurons, and increased dopamine release. FTY720 directly inhibited MPTP-induced microglial activation in the SNpc, suppressed the production of interleukin (IL)-6, IL-1β, and tumor necrosis factor-α in BV-2 microglial cells treated with 1-methyl-4-phenylpyridinium (MPP + ), and subsequently decreased apoptosis in SH-SY5Y neuroblastoma cells. Moreover, in MPP + -treated BV-2 cells and primary microglia, FTY720 treatment significantly attenuated the increases in the phosphorylation of PI3K/AKT/GSK-3β, reduced ROS generation and p65 activation, and also inhibited the activation of NLRP3 inflammasome and caspase-1. In conclusion, FTY720 may reduce PD progression by inhibiting NLRP3 inflammasome activation via its effects on ROS generation and p65 activation in microglia. These findings provide novel insights into the mechanisms underlying the therapeutic effects of FTY720, suggesting its potential as a novel therapeutic strategy against PD. Graphical Abstract FTY720 may reduce ROS production by inhibiting the PI3K/AKT/GSK-3β signaling pathway, while at the same time reducing p65 phosphorylation, thus decreasing NLRP3 inflammasome activation through these two pathways, ultimately reducing microglia activation-induced neuronal damage.

L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice

L-F001, a multifunctional ROCK inhibitor prevents paraquat-induced cell death through attenuating ER stress and mitochondrial dysfunction in PC12 cells

L-F001, a Novel Multifunctional ROCK Inhibitor, Suppresses Neuroinflammation in Vitro and in Vivo: Involvement of NF-κB Inhibition and Nrf2 Pathway Activation.

Multitarget Intervention of Fasudil in the Neuroprotection of Dopaminergic Neurons in MPTP-mouse Model of Parkinson's Disease

Rho kinase II interference by small hairpin RNA ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Discovery of A Benzofuran Derivative (mbpta) As A Novel Rock Inhibitor That Protects Against Mpp+-Induced Oxidative Stress and Cell Death in Sh-Sy5y Cells

FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation

J24335 exerts neuroprotective effects against 6-hydroxydopamine-induced lesions in PC12 cells and mice

L-F001, a Multifunctional Fasudil-Lipoic Acid Dimer Prevents RSL3-Induced Ferroptosis Via Maintaining Iron Homeostasis and Inhibiting JNK in HT22 Cells.

Simply combining fasudil and lipoic acid in a novel multitargeted chemical entity potentially useful in central nervous system disorders

Fty720 Attenuates 6-Ohda-associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models

Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation Via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-induced Model of Parkinson's Disease

Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease.

A Novel GTP-binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson's Disease Models.

Benfotiamine Protects MPTP-induced Parkinson’s Disease Mouse Model Via Activating Nrf2 Signaling Pathway

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

The Parthenolide Derivative ACT001 Synergizes with Low Doses of L-DOPA to Improve MPTP-induced Parkinson’s Disease in Mice

Neuroprotective Effects of the Andrographolide Analogue AL-1 in the MPP+/MPTP-induced Parkinson's Disease Model in Vitro and in Mice

Neuroprotective Effect of β-Lapachone in MPTP-Induced Parkinson’s Disease Mouse Model: Involvement of Astroglial p-AMPK/Nrf2/HO-1 Signaling Pathways

Α-Lipoic Acid Protects Dopaminergic Neurons Against MPP+-induced Apoptosis by Attenuating Reactive Oxygen Species Formation.

Polydatin Prevents Lipopolysaccharide (LPS)-Induced Parkinson's Disease via Regulation of the AKT/GSK3β-Nrf2/NF-κB Signaling Axis